Intellia Therapeutics to Present at March Investor Healthcare Conferences
01 Mars 2017 - 1:10PM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing
company focused on the development of potentially curative
therapeutics using CRISPR/Cas9 technology, announced that company
senior leaders will present at key March investor healthcare
conferences, including the Cowen and Company 37th Annual Health
Care Conference, the Goldman Sachs Third Annual Innovation
Symposium, and the Oppenheimer 27th Annual Healthcare Conference.
Details of the upcoming presentations are as follows:
Wednesday, March 8th Cowen and Company
37th Annual Health Care ConferenceWho: Nessan Bermingham,
Ph.D., chief executive officer & founderLocation: Boston,
MassachusettsPresentation Time: 8:40 am ET
Wednesday, March 15thThe Goldman Sachs
Third Annual Innovation SymposiumGene Editing and CRISPR
PanelWho: Nessan Bermingham, Ph.D., chief executive officer &
founderLocation: New York, New YorkPanel Time: 10:15 am ET
Wednesday, March 22nd The Oppenheimer
27th Annual Healthcare ConferenceWho: John Leonard, M.D.,
executive vice president, R&D Location: New York, New
YorkPresentation Time: 2:45 pm ET
Individuals may access the presentations for
available conferences via live webcast on the Intellia website at
www.intelliatx.com under "Events & Presentations" in the
"Investor Relations" section. When available, replays of these
webcasts will be available on the site for 90 days following the
live events.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company,
focused on the development of proprietary, potentially curative
therapeutics using the CRISPR/Cas9 system. Intellia believes the
CRISPR/Cas9 technology has the potential to transform medicine by
permanently editing disease-associated genes in the human body with
a single treatment course. Our combination of deep scientific,
technical and clinical development experience, along with our
leading intellectual property portfolio, puts us in a unique
position to unlock broad therapeutic applications of the
CRISPR/Cas9 technology and create a new class of therapeutic
products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at
intelliatx.com; Follow us on Twitter @intelliatweets.
Media Contact:
Jennifer Mound Smoter
Senior Vice President, External Affairs & Communications
+1 (857) 706-1071
jenn.smoter@intelliatx.com
Investor Contact:
Graeme Bell
Chief Financial Officer
+1 (857) 706-1081
graeme.bell@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024